Wedbush Reiterates “Underperform” Rating for EIKN (NASDAQ:EIKN)

EIKN (NASDAQ:EIKN)‘s stock had its “underperform” rating reiterated by analysts at Wedbush in a report released on Tuesday,Benzinga reports. They currently have a $7.00 price target on the stock. Wedbush’s target price would indicate a potential downside of 30.56% from the company’s previous close.

EIKN has been the subject of a number of other reports. Zacks Research upgraded EIKN to a “hold” rating in a report on Friday, February 27th. Wall Street Zen upgraded shares of EIKN from a “sell” rating to a “hold” rating in a research note on Saturday, March 28th. Mizuho started coverage on shares of EIKN in a research report on Monday, March 2nd. They set an “outperform” rating and a $26.00 price target on the stock. JPMorgan Chase & Co. initiated coverage on shares of EIKN in a research note on Monday, March 2nd. They issued an “overweight” rating and a $29.00 price objective for the company. Finally, Bank of America assumed coverage on shares of EIKN in a report on Monday, March 2nd. They issued a “buy” rating and a $34.00 price objective for the company. Five research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $25.60.

EIKN Stock Down 4.7%

Shares of NASDAQ EIKN opened at $10.08 on Tuesday. EIKN has a twelve month low of $9.46 and a twelve month high of $17.40.

EIKN Company Profile

We are a late-stage clinical biopharmaceutical company dedicated to building a global, fully-integrated organization developing important, innovative medicines to address serious unmet medical needs. We are led by world-renowned drug developers Dr. Roger M. Perlmutter, M.D., Ph.D., and Dr. Roy Baynes, M.D., Ph.D. Our vision is to become a generational leader, by purposefully integrating traditional biology research with advanced engineering to develop better medicines faster. Our initial focus is oncology, where we are advancing a pipeline of drug candidates targeting areas of high unmet need in large indications.